Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Serina TherapeuticsSER +1.49%12 3-Year Book Growth Rate is 53.10% as of Jun. 2026, which is at its 10-year median of 53.10. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,128 Biotechnology companies, Serina Therapeutics ranks better than 94.77% on this metric.
During the past 3 years, the average Book Value per Share Growth Rate was 53.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Serina Therapeutics was 53.10% per year. The lowest was 53.10% per year. And the median was 53.10% per year.
Serina Therapeutics (AMEX:SER) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Serina Therapeutics 3-Year Book Growth Rate Related Terms
SER vs HRTX, IMA, BOLD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Serina Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's 3-Year Book Growth Rate falls into.
Serina Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 53.10% mean?
Serina Therapeutics (SER) has a 3-Year Book Growth Rate of 53.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Serina Therapeutics and its competitors. This is near median its historical median of 53.10. Over the past decade, Serina Therapeutics' 3-Year Book Growth Rate has ranged from 53.10 to 53.10. According to the industry distribution chart, Serina Therapeutics ranks #59 out of 1128 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Serina Therapeutics' 3-Year Book Growth Rate too high?
Serina Therapeutics' current 3-Year Book Growth Rate of 53.10% is near median its 10-year median of 53.10. Over the past 10 years, this metric has ranged from a low of 53.10 to a high of 53.10. Based on the distribution chart, Serina Therapeutics ranks #59 out of 1128 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' 3-Year Book Growth Rate compare to HRTX and IMA?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #59 out of 1128 companies for 3-Year Book Growth Rate. This places Serina Therapeutics in the top 5% of its industry — outperforming the majority of peers. Historically, Serina Therapeutics' own 3-Year Book Growth Rate has ranged from 53.10 to 53.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Serina Therapeutics and its competitors. Serina Therapeutics's current 3-Year Book Growth Rate is 53.10%, which is near median its own 10-year median of 53.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current 3-Year Book Growth Rate of 53.10%. The current 3-Year Book Growth Rate is 53.10%, which is near median its 10-year median of 53.10. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Serina Therapeutics (SER), the current 3-Year Book Growth Rate is 53.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score
Get the complete analysis for SER
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SER has been successfully added to your 
